Background {#Sec1}
==========

Multiple sclerosis (MS) is a chronic relapsing disorder of the central nervous system characterized by inflammation, multifocal demyelination, and neuronal and axonal damage \[[@CR1]\]. The majority of MS patients initially present with relapsing--remitting MS (RRMS) that frequently develops to a progressive disease course \[[@CR1]\]. The prevalence of MS varies according to geographic location from 10 to 20 per 100,000 in Central and South America to \>30 per 100,000 in northern Europe and North America \[[@CR2]\].

Immunomodulating disease-modifying therapies (DMTs) have been shown to improve multiple measures of disease activity in RRMS patients, including the annualized relapse rate (ARR), proportion of relapse-free individuals, and accumulation of T2 lesion burden \[[@CR3]--[@CR5]\]. However, these agents are only partially effective in controlling disease progression; studies have reported treatment interruption or discontinuation because of lack of tolerability, progression of disability, or inadequate clinical response \[[@CR6]\]. Additionally, the development of neutralizing antibodies, specifically with interferon β products (IFNs) and natalizumab \[[@CR7]\], can interfere with the biologic response \[[@CR8]\].

Converting to another DMT class represents one treatment strategy for MS patients with an inadequate response to first-line treatments or intolerant side effects \[[@CR9]\]. Expert guidance on the specific steps of a conversion has been reported \[[@CR10]\]; however, the lack of information on outcomes in different populations \[[@CR11]\] results in limited guidance on regional patient considerations.

The COPTIMIZE study was designed to monitor clinical outcomes after converting from failing or ineffective DMT therapy for RRMS to glatiramer acetate (GA) in a prospective way. GA is approved in 57 countries as a 20 mg daily subcutaneous (s.c.) injection for reducing relapse frequency in patients with RRMS. It has long-term efficacy and safety data, with the longest continuous treatment exposure of more than 20 years \[[@CR12], [@CR13]\]. The primary results of COPTIMIZE, presented elsewhere \[[@CR14]\], indicate that a conversion to GA is associated with positive treatment outcomes and that the benefits vary depending on patients' reasons for changing. The primary objective of the present sub-analysis is to determine whether benefits associated with converting to GA were affected by therapeutic strategies and patient selection in different geographic locations: Latin America (LA), Canada and Western Europe (CWE), and Eastern Europe (EE).

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Study design, patient eligibility criteria, and conduct of the COPTIMIZE have been previously reported \[[@CR14]\]. Briefly, this post-hoc subgroup analysis attempted to describe any variation in results that might exist between three predefined geographical areas: LA (Argentina, Brazil, Chile, Mexico, Venezuela), CWE (Belgium, Canada, Denmark, France, Greece, Ireland, Portugal, Netherlands, Norway, Sweden), and EE (Hungary, Romania, Slovakia). Countries were grouped into regions based on similarity of healthcare systems, physician approaches \[[@CR15]\], available treatment options \[[@CR10], [@CR16]\], and epidemiological characteristics of the population (disease prevalence, demographics, etc.) \[[@CR2]\]. All countries investigated in this observational study reported the use of IFN-β and GA at baseline, with no anticipated systematic differences between regions. This study was conducted in accordance with the 18th World Medical Assembly (Helsinki) recommendations and amendments, as well as guidelines for Good Epidemiology Practice. The study protocol was approved by the institutional review boards and independent ethics committees at all participating study locations in each individual country; each site ensured all necessary regulatory submissions in accordance with local regulations including local data protection regulations. All patients provided informed, written consent according to local independent review board ruling.

Study endpoints {#Sec4}
---------------

The primary objective was to assess the disease course in RRMS patients converting from IFN treatment to GA as measured by the primary endpoints of ARR and annualized rate of deterioration (ARD) (confirmed progression of Expanded Disability Status Scale \[EDSS\]/worsening mobility scores). Secondary data collected included reasons for DMT conversion, characteristics of patients failing to benefit from previous DMT, and change in EDSS and modified fatigue impact scale (MFIS) scores. Also recorded were quality of life (QoL) changes following GA conversion as measured by the Functional Assessment of Multiple Sclerosis (FAMS), cognition changes as evaluated by the Paced Auditory Serial Addition Test (PASAT), depression as measured by Centre for Epidemiologic Studies Depression (CES-D) scale, and change in adverse events (AEs) following the conversion.

Statistical analyses {#Sec5}
--------------------

Statistical analyses of parameters in this observational study required comparison of at least two endpoint measures, pre- and post-GA conversion, with data represented by descriptive procedures and figures, if necessary. Adjustment for missing data was not required to maintain statistical integrity of the analyses, and annualized rates (primary endpoints) were calculated for each subject using all the available data. Other parameters, which provide additional data for evaluation of the patient status prior to and following conversion to GA, were reported in a non-obligatory manner. Tests of significance (signal rank test and binominal test) were used to measure changes in efficacy parameters from baseline to final examination. ARR and ARD pre- and post-conversion were analyzed using repeated measures analysis of covariance using the maximum likelihood ratio. Log transformation was implemented to the ARR and ARD to establish if there was a significant deviation from normality (i.e., *P* \< .001 using the Shapiro-Wilk test). The Wilcoxon signed rank test was used within groups for EDSS, MFIS, FAMS, PASAT, and CES-D.

Results {#Sec6}
=======

Patient disposition {#Sec7}
-------------------

Overall, 672 patients from 148 centers across 19 countries were enrolled, with 668 patients included in the analysis (excluding four patients from Taiwan): 263 LA, 248 CWE, and 157 EE patients (Table [1](#Tab1){ref-type="table"}). Patient characteristics were comparable at baseline between regions, excluding EE patients, who were younger and reported fewer comorbidities and concomitant medications than LA and CWE patients. Baseline disease characteristics that were similar across regions (Table [1](#Tab1){ref-type="table"}) included disease duration from onset, diagnosis, and mean ARR. Distribution of baseline ARR score varied slightly, with the majority of patients experiencing between 0 and 1.25 events/year. LA patients reported the highest disability (baseline EDSS) and the highest frequency of RRMS with incomplete remissions. At baseline, the majority of patients had received one previous DMT regimen in one class of agents (Table [1](#Tab1){ref-type="table"}). Reports of flu-like symptoms were the most common reason for converting to GA. The majority of patients in all regions were converted from IFN-β therapy.Table 1Baseline patient demographics, disease characteristics, and DMT historyCharacteristicsLA (*n* = 263)CWE (*n* = 248)EE (*n* = 157)Female gender, *n* (%)189 (71.9)175 (70.6)108 (68.8)Mean age, years (± SD)40.1 (10.1)43.0 (10.2)34.7 (8.4)Patients with comorbidities at recruitment, *n* (%)27 (10.3)19 (7.7)8 (5.1)  Depression13 (4.9)6 (2.4)1 (0.6)  Anxiety2 (0.8)1 (0.4)1 (0.6)  Hypertension1 (0.4)4 (1.6)2 (1.3)Patients with concomitant therapies at time of recruitment, *n* (%)24 (9.1)15 (6.1)7 (4.5)  Psychoanaleptics14 (5.3)5 (2.0)1 (0.6)  Antiepileptics6 (2.3)2 (0.8)1 (0.6)  Thyroid therapy3 (1.1)3 (1.2)N/AMean disease duration since onset, months (± SD)^a^98.0 (82.9)100.1 (84.4)92.3 (63.9)Mean disease duration since diagnosis, months (± SD)^b^68.9 (59.6)72.1 (70.7)67.9 (48.5)Mean ARR, events/year (± SD)^c^1.0 (0.8)0.8 (0.6)0.7 (0.5)Patients in ARR range, *n* (%\*)  0.00--1.25166 (67.5)193 (84.6)130 (88.4)  1.25--3.2578 (31.7)35 (15.4)17 (11.6)  \>3.252 (0.8)0 (0.0)0 (0.0)  Data unavailable172010Clinical type of MS, *n* (%^d^)  RRMS with incomplete remissions171 (67.6)117 (47.6)91 (59.1)  RRMS with complete remission80 (31.6)122 (49.6)62 (40.3)  Clinically isolated syndrome0 (0.0)0 (0.0)1 (0.6)  Other2 (0.8)7 (2.8)0 (0.0)  Data unavailable1023Diagnosed with MS by criteria, *n* (%^d^)  McDonald217 (83.8)194 (78.5)143 (92.3)  Poser42 (16.2)53 (21.5)12 (7.7)  Data unavailable412Mobility, *n* (%^d^)  Asymptomatic45 (19.8)46 (20.0)20 (14.9)  Able to walk unaided for \>500 m96 (42.3)126 (54.8)112 (83.6)  Able to walk unaided for \<500 m30 (13.2)27 (11.7)2 (1.5)  Walking with bilateral support13 (5.7)9 (3.9)0 (0.0)  Walking with unilateral support33 (14.5)18 (7.8)0 (0.0)  Need of a wheelchair outdoors10 (4.4)4 (1.7)0 (0.0)  Data unavailable361823Mean EDSS score (± SD)^e^3.5 (2.2)2.8 (1.9)2.6 (1.0)Mean CES-D score (0--60) (± SD)^f^16.0 (11.7)16.0 (10.3)20.6 (19.5)Mean MFIS score (0--84) (± SD)^g^32.3 (19.7)31.4 (19.1)33.7 (27.9)Mean FAMS score (0--176) (± SD)^h^109.4 (37.8)100.8 (34.3)77.7 (59.4)Mean PASAT score (0--60) (± SD)^i^35.6 (13.6)36.7 (15.7)51.8 (5.9)Mean observation duration, months (± SD)^j^20.5 (6.3)18.6 (7.7)19.2 (7.8)Number of DMT classes used (%) (converters only)  1206 (85.5)201 (83.4)143 (92.9)  232 (13.3)38 (15.8)10 (6.5)  33 (1.2)2 (0.8)1 (0.6)  Non-converters2273Previous type and mode of IFN-β used, %^k^  IFN-β-1a (i.m.)30.336.047.4  IFN-β-1b (s.c.)30.325.930.5  IFN-β-1a (s.c.)35.530.721.4Reason for conversion to GA, *n* (%)^l^  Lack of previous DMT efficacy171 (71.0)78 (32.4)92 (59.7)  Presence of neutralizing antibodies1 (0.4)44 (18.3)2 (1.3)  Intolerable adverse events associated with previous DMT98 (40.7)132 (54.8)55 (35.7)  Flu--like symptoms67 (27.8)73 (30.3)40 (26.0)  Subjective29 (12.0)37 (15.4)17 (11.0)  Skin reactions15 (6.2)14 (5.8)20 (13.0)  Blood work7 (2.9)18 (7.5)4 (2.6)  Others21 (8.7)39 (16.2)4 (2.6)  Not specified1 (0.4)1 (0.4)0 (0.0)  Other8 (3.3)21 (8.7)36 (23.4)  Non-converters2273Discontinuation of GA, *n* (%)66 (25.1)77 (31.1)30 (19.1)  Perceived lack of efficacy by physician19 (7.2)7 (2.8)16 (10.2)  Perceived lack of efficacy by patient7 (2.7)14 (5.7)6 (3.8)  Adverse events9 (3.4)17 (6.9)4 (2.5)  Lost to follow-up14 (5.3)24 (9.7)2 (1.3)  Other15 (5.7)8 (3.2)3 (1.9)^a^Missing data in 24 LA, 28 CWE, and 5 EE patients^b^Missing data in 15 LA, 21 CWE, and 4 EE patients^c^Missing data in 7 LA, 2 CWE, and 3 EE patients^d^Adjusted percentage of patients with data available^e^Missing data in 55 LA, 9 CWE, and 8 EE patients^f^Missing data in 116 LA, 103 CWE, and 150 EE patients^g^Missing data in 113 LA, 118 CWE, and 150 EE patients^h^Missing data in 55 LA, 9 CWE, and 8 EE patients^i^Missing data in 197 LA, 103 CWE, and 150 EE patients^j^Missing data in 11 LA, 17 CWE, and 10 EE patients^k^Missing data in 32 LA, 20 CWE, and 3 EE patients^l^Adjusted percentage of patients with data available. Patients were allowed to cite ≥1 reason for conversion to GA. Therefore, the percentage may exceed 100 %

Annualized relapse rate {#Sec8}
-----------------------

ARR was significantly decreased in all groups following the conversion to GA (Fig. [1](#Fig1){ref-type="fig"}). LA patients, who had the highest baseline ARR rate, also had the greatest ARR reduction (1.05 ± 0.78 pre-conversion to 0.34 ± 0.86 post-conversion; *P* \< .0001, Shapiro-Wilk test). ARR went from 0.73 ± 0.58 to 0.34 ± 0.84 (*P* \< .0001) in CWE patients and 0.71 ± 0.50 to 0.24 ± 0.92 (*P* \< .0001) in EE patients.Fig. 1Reduction of annualized relapse rate by geographic region. ^a^ *P* \< .0001 vs. baseline. \*The overall population size does not each the sum of the three individual regions due to four patients in Taiwan that excluded from the regional analysis. *ARR* annualized relapse rate

### Disease progression {#Sec9}

In total, 499 patients had ≥1 EDSS assessment after baseline examination, with the overall population showing a significant increase in EDSS score (i.e., progression to worse disability) from 2.9 at baseline to 3.02 at final follow-up, post-switch (*P* = .0256). There was a significant difference between regions in the degree of change in EDSS score while on GA therapy (*P* = .0230, Wilcoxon signed-rank test), driven by a significant increase in CWE patients' EDSS score of 0.26 ± 1.18 (*P* = .0016). Neither LA nor EE patients had significant changes in mean EDSS score from baseline. Improved (i.e., numerically lowered) EDSS scores were seen in 32.5 %, 24.4 %, and 33.8 % of LA, CWE, and EE patients, respectively. There was no change from baseline in 35.8 %, 34.9 %, and 41.2 %, respectively. Deterioration was reported in 31.8 %, 40.7 %, and 25.0 %, respectively.

### Disease activity {#Sec10}

Disease activity while receiving GA varied. LA patients reported the highest incidence of frequent exacerbations and of fast progression of MS (Table [2](#Tab2){ref-type="table"}). Fewer LA patients reported rarely experiencing exacerbations (27.9 %, vs. 43.5 % CWE and 66.0 % EE patients).Table 2MS disease activity over the 2-year study periodPatients, *n* (%)LACWEEE(*n* = 251)(*n* = 246)(*n* = 153)Stable MS (Stage 1)37 (14.7)47 (19.1)22 (14.4)Rare exacerbations (≤1 per year, Stage 2a)70 (27.9)107 (43.5)101 (66.0)Slow progression (≤0.5 EDSS points per year, Stage 2b)48 (19.1)35 (14.2)6 (3.9)Frequent exacerbations (\>1 per year, Stage 3a)80 (31.9)43 (17.5)21 (13.7)Fast progression (\>0.5 EDSS points per year, Stage 3b)11 (4.4)3 (1.2)1 (0.7)Not classified/not available5 (2.0)11 (4.5)2 (1.3)

### Change in mobility {#Sec11}

The majority of patients showed no change in mobility scores (63.4 %, 62.8 %, and 67.5 % of LA, CWE, and EE patients, respectively). Mobility scores improved in 17.1 % LA and 18.9 % CWE patients, with a significant improvement in 23.0 % of EE patients (*P* = .0079). Mobility scores deteriorated in 19.4 %, 18.4 %, and 9.5 % of LA, CWE, and EE patients, respectively. Data were missing for 47 LA, 52 CWE, and 31 EE patients.

Secondary endpoints {#Sec12}
-------------------

In LA patients, there was a significant improvement in the mean difference in MFIS score from baseline (6.9 ± 15.4; *P* \< .0001) (Fig. [2](#Fig2){ref-type="fig"}). EE patients and CWE patients experienced a nonsignificant increase from baseline of 6.7 ± 18.2 and 0.4 ± 13.6, respectively.Fig. 2Change in fatigue, depression, and cognition scores by geographic region. ^a^ *P* \< .0001 for Latin America vs. Canada/Western Europe at final follow-up. ^b^ *P* \< .0001 for change from baseline. ^*c*^ *P* \< .0001 for change from baseline. ^*d*^ *P* = .0030 for change from baseline. ^e^ *P* = .0024 for change from baseline. *CES-D* Centre for Epidemiologic Studies Depression, *MFIS* Modified Fatigue Impact Scale, *PASAT* Paced Auditory Serial Addition Test, *WE* Western Europe

Only LA patients showed a significant change in QoL, with an improvement in mean FAMS score of 18.5 ± 46.5 from baseline (*P* = .0008). CWE patients had a mean FAMS increase of 0.6 ± 20.5, while EE patients showed a decrease of 2.3 ± 8.8 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Change in quality of life score by geographic region. ^a^ *P* = .0012 for Latin America vs. Canada/Western Europe at final follow-up. ^b^ *P* = .0008 for change from baseline. *FAMS* Functional Assessment of Multiple Sclerosis

LA patients reported a significant improvement in depression symptoms, with a decrease in mean CES-D score of 4.6 ± 10.9 (*P* \< .0001) (Fig. [2](#Fig2){ref-type="fig"}). CWE patients showed a numerical increase in mean CES-D score of 1.7 ± 9.9, while EE patients showed a decrease of 2.4 ± 10.8. These changes were not statistically significant.

Patients from all regions showed an improvement in mean PASAT (cognition) scores (Fig. [2](#Fig2){ref-type="fig"}). LA patients had the greatest improvement, with a statistically significant mean increase of 6.3 ± 9.1 in PASAT score (*P* = .0030). CWE patients also showed a statistically significant mean increase of 3.8 ± 9.6 (*P* = .0024), while EE patients had a smaller mean increase of 0.8 ± 5.3 (NS).

LA patients reported the highest efficacy with GA than the previous drug (70.0 %; *P* \< .0001), followed by EE and CWE patients (42.4 % and 41.6 %, respectively; both *P* \< .0001). LA patients reported the lowest percentage of "feeling worse" on GA therapy (3.9 %), with EE patients reporting the highest percentage (15.2 %), followed by CWE patients (6.1 %). There was no change in perception of efficacy in 26.2 %, 52.2 % and 42.4 % of LA, CWE, and EE patients, respectively (Additional file [1](#MOESM1){ref-type="media"}).

Safety {#Sec13}
------

AEs reported in all three regions are listed in Table [3](#Tab3){ref-type="table"}. Patients from all regions experienced statistically significant improvements in AEs with GA use (*P* \< .0001).Table 3Adverse events (AEs)Patients, events/patients (%^a^)LA (*n* = 263)CWE (*n* = 248)EE (*n* = 157)Most common AEs by preferred term  Dyspnea5/4 (1.5)4/3 (1.2)1/1 (0.6)  Syncope2/2 (0.8)2/2 (0.8)0/0 (0.0)  Injection site reaction2/2 (0.8)8/8 (3.2)0/0 (0.0)  Injection site pain2/2 (0.8)14/10 (4.0)0/0 (0.0)  Injection site induration1/1 (0.4)5/5 (2.0)0/0 (0.0)  Fatigue1/1 (0.4)3/3 (1.2)0/0 (0.0)  Arthralgia1/1 (0.4)3/3 (1.2)0/0 (0.0)  Rash0/0 (0.0)2/2 (0.8)2/2 (1.3)  Anxiety0/0 (0.0)1/1 (0.4)1/1 (0.6)Most common AE classified by system organ class  General disorders and administration site conditions16/13 (4.9)55/32 (12.9)5/4 (2.6)  Nervous system disorders10/10 (3.8)9/8 (3.2)0/0 (0.0)  Respiratory, thoracic, and mediastinal disorders7/6 (2.3)4/3 (1.2)0/0 (0.0)Severity of AE, events/patients  Mild19/12 (4.6)40/28 (11.3)0/0 (0.0)  Moderate22/12 (4.6)62/38 (15.3)5/5 (3.2)  Severe13/6 (2.3)14/9 (3.6)5/3 (1.9)  Data unavailable4/2 (0.8)7/5 (2.0)2/2 (1.3)Patient-reported assessment of AEs after glatiramer acetate treatment^b^  Improved with glatiramer acetate209 (80.4)162 (66.1)58 (38.4)  Same with glatiramer acetate41 (15.8)62 (25.3)87 (57.6)  Worse with glatiramer acetate10 (3.9)21 (8.6)6 (4.0)  Data unavailable336^a^Percentage reported as the proportion of patients experiencing events^b^Adjusted percentage of patients with data available

Discussion {#Sec14}
==========

Converting to another class of immunomodulatory therapy represents one treatment strategy in MS patients who fail to respond adequately to first-line treatments \[[@CR10]\]. However, this strategy may not always be beneficial because of geographical variations in treatment regimens and therapeutic strategies. For example, GA and IFN-β are typically the first-line treatment options in MS treatment algorithms, regardless of the geographical region \[[@CR11]\]. However, some LA neurologists prescribe azathioprine because of limited DMT access or because the drugs are unavailable on healthcare plans \[[@CR16], [@CR17]\]. Expert guidance on the specific steps of a conversion have begun to be published, suggesting a conversion in therapy may be considered when there is a high level of concern about relapse rates, progression of MS and magnetic resonance imaging outcomes, a medium level of concern about any two factors, or a low level of concern about all three factors \[[@CR10]\]. The general nature of the guidelines is due to inconsistent results with converting.

In this sub-analysis of the COPTIMIZE trial, converting to GA was well tolerated, reduced disease progression and activity, and improved other secondary endpoints in patients across all three regions to varying degrees. LA patients experienced the largest reduction in ARR; however, their baseline ARR was much higher than CWE and EE patients. Ultimately, all three regions reached similar ARR. LA patients had higher baseline rates of comorbidities and incomplete previous remissions than the other two regions, as well as significant improvements in QoL, depression, fatigue, and cognition scores. They also had a better perception of the benefits of a GA conversion in terms of efficacy and AEs than CWE and EE patients.

These discrepancies may be due to differences in healthcare standards and environmental factors between the different regions. For example, the US, Canada, and LA have clinical treatment guidelines that vary in the topics discussed and the use of GA, IFN-β, natalizumab, dalfampridine, and fingolimod \[[@CR10], [@CR16]--[@CR18]\]. Also, it is possible that patients from different regions may have different epidemiological characteristics and comorbidities \[[@CR16]\]. These regional differences cannot be adjusted in such a study, where the observational, non-interventional design carries inherent analytical limitations.

Now that consensus guidelines have defined a suboptimal treatment response, and neurodegenerative activity has been identified even in early stages of disease \[[@CR19], [@CR20]\], converting to another DMT class represents a logical treatment strategy in patients who fail to respond adequately to first-line treatments. Our results suggest that more attention is required regarding the importance of establishing formal conversion algorithms that account for geographic variability, ensuring that all patients who could benefit from such an approach are managed in a timely and optimal manner.

Despite study limitations, our observations emphasize the importance of changing a therapy regimen, in particular IFN-based, to improve efficacy and/or overcome treatment intolerance that would otherwise compromise compliance. This is in alignment with previous studies of this strategy \[[@CR9], [@CR21]\].

Conclusions {#Sec15}
===========

All patients experienced significant improvements in ARR regardless of geographic region. There were differences between regions in patients' baseline parameters, comorbidities, and reasons for converting to GA treatment. The evolution of guidelines regarding suboptimal treatment response and DMT conversion has the potential to affect strategies for monitoring and treating patients across all geographies and to improve clinical and patient-reported outcomes.

Additional files {#Sec16}
================

Additional file 1:**Patient perception of glatiramer acetate treatment efficacy by geographic region.** ^a^ *P* \< .0001 for Latin America vs. other geographic areas. (PDF 7 kb)Additional file 2:**COPITIMIZE: Main Investigator sites.** (DOCX 14 kb)
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